![](/images/graphics-bg.png)
Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy
Joint Authors
Granieri, E.
Fainardi, Enrico
Elia, Francesca
Bergamaschi, Roberto
Trentini, Alessandro
Manfrinato, Maria Cristina
Volta, Carlo Alberto
Bellini, Tiziana
Delbue, Serena
Castellazzi, Massimiliano
Franciotta, D.
Gastaldi, Matteo
Source
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-06-02
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Background.
Natalizumab is a highly effective treatment approved for multiple sclerosis (MS).
The opening of the blood-brain barrier mediated by matrix metalloproteinases (MMPs) is considered a crucial step in MS pathogenesis.
Our goal was to verify the utility of serum levels of active MMP-2 and MMP-9 as biomarkers in twenty MS patients treated with Natalizumab.
Methods.
Serum levels of active MMP-2 and MMP-9 and of specific tissue inhibitors TIMP-1 and TIMP-2 were determined before treatment and for 21 months of therapy.
Results.
Serum levels of active MMP-2 and MMP-9 and of TIMP-1 and TIMP-2 did not differ during the treatment.
The ratio between MMP-9 and MMP-2 was increased at the 15th month compared with the 3rd, 6th, and 9th months, greater at the 18th month than at the 3rd and 6th months, and higher at the 21st than at the 3rd and 6th months.
Discussion.
Our data indicate that an imbalance between active MMP-9 and active MMP-2 can occur in MS patients after 15 months of Natalizumab therapy; however, they do not support the use of serum active MMP-2 and active MMP-9 and TIMP-1 and TIMP-2 levels as biomarkers for monitoring therapeutic response to Natalizumab.
American Psychological Association (APA)
Castellazzi, Massimiliano& Bellini, Tiziana& Trentini, Alessandro& Delbue, Serena& Elia, Francesca& Gastaldi, Matteo…[et al.]. 2016. Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy. Disease Markers،Vol. 2016, no. 2016, pp.1-7.
https://search.emarefa.net/detail/BIM-1103791
Modern Language Association (MLA)
Castellazzi, Massimiliano…[et al.]. Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy. Disease Markers No. 2016 (2016), pp.1-7.
https://search.emarefa.net/detail/BIM-1103791
American Medical Association (AMA)
Castellazzi, Massimiliano& Bellini, Tiziana& Trentini, Alessandro& Delbue, Serena& Elia, Francesca& Gastaldi, Matteo…[et al.]. Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy. Disease Markers. 2016. Vol. 2016, no. 2016, pp.1-7.
https://search.emarefa.net/detail/BIM-1103791
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1103791